Physician profile
Mitra Emami
NPI 1720145147
$12,124.92
in general payments reported to CMS, 2019-2025
50 companies · $1,656 in 2025
The $1,656 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,212 · 2020: $994 · 2021: $2,246 · 2022: $1,552 · 2023: $1,798 · 2024: $2,667 · 2025: $1,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,032 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,032.49 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,241.92 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Eisai INC. | $1,198.75 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,025.87 | 2020-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $835.71 | 2021-2025 | |
| Catalyst Pharmaceuticals, INC. | $802.62 | 2023-2025 | Fycompa |
| Biogen, INC. | $689.07 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Sk Life Science, INC. | $571.09 | 2021-2025 | |
| Lundbeck LLC | $532.56 | 2019-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $461.35 | 2019-2025 | Ultomiris |
| Avanir Pharmaceuticals, INC. | $425.61 | 2019-2022 | |
| Neurelis, INC. | $344.33 | 2024-2025 | Valtoco |
| Celgene Corporation | $342.73 | 2020-2024 | Zeposia |
| Lilly USA, LLC | $332.08 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $283.21 | 2019-2025 | Ingrezza |
| Pfizer INC. | $258.02 | 2023-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitra Emami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.